Blood samples (20 mL) will be collected to obtain plasma used to test for exploratory biomarkers. Blood samples will be collected at Visit 0 (baseline), at every
16 weeks during the study, at end of treatment due to disease progression, and during treatment after disease progression in the case of isolated,
asymptomatic progression of disease in the CNS.